From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy: It Is Surely In Real Trouble Now, the Fat Lady awaits

By Nigel Somerville, the Deputy Sheriff of AIM | Saturday 11 February 2023

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

It seems that no amount of ramping can help AIM-listed Advanced Oncotherapy (AVO) now. The company is in deep shit – and has essentially admitted as much. I would suggest also that the recent note from pay-as-you-go “researcher” (to be polite) Hardman is also an almighty sell signal. At the root of the problem is the cash-guzzling nature of the business, but with a 25p par price and the shares now at just 7.5p it is clear that shareholders are about to take a bath. Or the whole shooting match could follow fellow proton therapy outfit Rutherford Health (RUTH - ex-of the Aquis lobster pot) to the great central bank in the sky. Anyone holding is, in my view, insane.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Time left: 22:42:04